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Daniel Furst, M.D.
Rheumatology division,
University of California, Los Angeles (UCLA), USA
Prof. Furst, a superb Rheumatology professor is the direc-
tor of Interventional Therapeutics at UCLA Medical Center.
He has expertise in clinical pharmacology of anti-rheumatic
drugs, scleroderma and rheumatoid arthritis. A member of
many committees concerned with rheumatic therapeutics and
the Arthritis Advisory Committee for the FDA. He is Chair-
man of the Innovative Therapies Meeting of the American
College of Rheumatology (ACR) and of Standing Committee
on Clinical Trials for the International League Against Rheu-
matism (ILAR). He is on the editorial board of several famous
journals and an editorial reviewer for Arthritis and Rheuma-
tism, New England Journal of Medicine, Journal of Clinical
Investigation and the Annals of Rheumatic Diseases. Prof.
Furst has published more than 400 articles and 12 books.
Loı¨c Guillevin, M.D.
Internal Medicine Department,
Cochin Hospital, Paris-Descartes University, France
Prof. Guillevin is a well known pioneer in the ﬁeld of vas-
culitis who has been involved for many years in the manage-
ment and care of patients aﬀected by systemic vasculitides.
Being a highly respected vasculitis researcher, Prof. Guillevin
created the French Vasculitis Study Group (FVSG) improving
our knowledge concerning the pathophysiogenesis of vasculi-
tis, based upon developing laboratory research activities, opti-
mizing therapy, in conjunction with an attempt to reduce
sequelae related to the disease or its treatment. Prof. Guillevin
is the chairman of the European Federation of Internal Med-
icine (EFIM) Research Working GroupIt is an honor and challenge to take over the position of the
Editor in-Chief of The Egyptian Rheumatologist after a very
eminent Rheumatology star Prof. Bassel El Zorkany who took
the heavy responsibility to make this journal a forerunner;
being hosted and produced by the world’s top class publisher
‘Elsevier’.
The extended cumulative experience put The Egyptian
Rheumatologist among the leading Rheumatology journals in
Egypt, Middle East and Africa. Being founded 1964, the Egyp-
tian Society for Joint Diseases and Arthritis launched its jour-
nal and started the annual scientiﬁc conferences in 1977. The
Journal has been regularly published and the annual confer-
ence held ever since. With the continuous support of Prof.
Ayman El Garf (the Society President since 2001 till present)
and Prof. Khaled El Hadidi (Vice President) The Egyptian
Rheumatologist was able to take big steps ahead in 2011 as
the submission process became online giving the Journal an
international scope. The number of downloads has remarkably
increased during 2012 (5 times more compared to 2011) and
the Journal is now being recognized in over 75 countries. I
believe we will be publishing a considerable number of high-
quality original research articles and reviews from authors
around the world.
The Egyptian Rheumatologist is an international peer
reviewed, full text, open access journal that is quarterly
publishing the highest quality scientiﬁc and clinical papers.
The journal aims to provide rapid publication of all papers
both online and in hard copy.
This year (18–22 February, 2013), the Society eﬀectively
held its 35th annual meeting for the third time in a row at
the International Congress Centre in the unique City of Sharm
El Sheikh; one of the world’s most amazing international des-
tinations in Sinai, Egypt. This year’s congress theme was on
‘Recent Advances in the Management of Rheumatic Diseases’,
which stemmed from the ongoing eﬀorts to innovate and inﬂuxdoi.org/10.1016/S1110-1164(13)00033-1
Open access under CC BY-NC-ND license.new biologics. This has made it indispensable to try to settle
recommendations and guidelines for their use at diﬀerent dis-
ease stages.
With even more success, this year’s conference was out-
standing and special as it included many well known interna-
tional Rheumatology ﬁgures sharing with us the updates of
diﬀerent topics and interacting with the Society members. It
is an honor to have them accept joining the Editorial Board
which will deﬁnitely hold up and enrich the journal as well
as help us move forward with more conﬁdence and
achievements.
With pleasure and gratitude the following professors joined
Marco Matucci-Cerinic, M.D., Ph.D.
Rheumatology division,
University of Florence, Italy
Prof. Matucci-Cerinic is the director of Division of
Medicine and Rheumatology, University of Florence, Italy.
He is a member of the International Scleroderma Network
(ISN) Medical Advisory Board, and the featured expert in its
book, Voices of Scleroderma. Author of more than 200
scientiﬁc publications, he is considered a world thought leader
in scleroderma, angiogenesis and Raynaud’s phenomenon. He
is also actively involved in the organization of care of sclero-
derma patients in his country and in Europe. He is currently
Chairman of the EULAR Scleroderma Trial and Research
group (EUSTAR), and Vice President of the Scleroderma
Clinical Trials Consortium (SCTC) which is a key partner with
the ISN in scleroderma clinical research eﬀorts.
Xenofon Baraliakos, M.D.
Rheumatism Center, Ruhrgebiet Herne,
Ruhr-University, Bochum, Germany
Prof. Baraliakos, a renowned speaker and researcher in the
ﬁeld of spondyloarthritis gave us very interesting talks during
this year’s conference in order to increase our awareness on ax-
ial spondyloarthritis and brilliantly discussed with us updates
in treatment strategies and their consequences as well as how
the classiﬁcation criteria apply to real life situations. His con-
tribution to the Assessment of SpondyloArthritis international
Society (ASAS) and highly specialized researches are
remarkable.
I wish to extend my gratitude to the Associate Editors and
the members of the Editorial Board as they are the backbone
of this scientiﬁc endeavour. We could not envisage enhancing
this journal without the support and professionalism of scien-
tists interested in Rheumatology and wishing to make this
journal a success. There is an immense appreciation owed by
the Editorial Board members to the authors who have sub-
mitted papers over the years, the reviewers who helped the Edi-
torial Oﬃce reach the optimum decision for each submitted
manuscript and the readers who have maintained a continued
interest in the Journal.
I would like to emphasize the compelling reasons for
launching The Egyptian Rheumatologist as an open-access
journal in this ever expanding area of research, as well as
our aspirations and vision for the future. It is important to
have a journal which gives free access to its contents and pro-
motes high-quality research and intellectual output of scien-
tists who have limited access to main stream journals. We
intend to bridge the gap so that authors get a wider audience
for their high-quality scientiﬁc achievements. This is particu-
larly true for scientists whose ﬁrst language is not English.
Thus we will work in partnership with such authors to ensure
that their research is made freely available to the wider scien-
tiﬁc community.
The Journal invites manuscripts in the area of Rheumatol-
ogy – a broad-based theme that should appeal to the largest
possible audience interested in this subject. I look forward to
additional success and welcome any comments or suggestions
you may have that would promote the Journal.
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Editor-in-Chief
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